Jpmorgan Chase & CO Nuvectis Pharma, Inc. Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
A detailed history of Jpmorgan Chase & CO transactions in Nuvectis Pharma, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 192 shares of NVCT stock, worth $973. This represents 0.0% of its overall portfolio holdings.
Number of Shares
192
Previous 14,753
98.7%
Holding current value
$973
Previous $93,000
98.92%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding NVCT
# of Institutions
32Shares Held
1.65MCall Options Held
0Put Options Held
0-
Ronit Capital LLP563KShares$2.85 Million5.37% of portfolio
-
Vanguard Group Inc Valley Forge, PA301KShares$1.53 Million0.0% of portfolio
-
Baldwin Brothers LLC174KShares$882,8390.08% of portfolio
-
Black Rock Inc. New York, NY83.4KShares$422,8980.0% of portfolio
-
Geode Capital Management, LLC Boston, MA79.7KShares$404,1600.0% of portfolio
About Nuvectis Pharma, Inc.
- Ticker NVCT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 14,642,500
- Market Cap $74.2M
- Description
- Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src...